Propafenone USP
propafenone
CAS: 54063-53-5
Molecular Formula: C21H27NO3
Propafenone USP - Names and Identifiers
| Name | propafenone |
| Synonyms | propafenone PROPAFENONE Propafenone AKOS 215-08 Propafenone USP (RS)-Propafenone 1-[2-[2-oxo-3-(propylamino)propoxy]phenyl]-3-phenyl-1-propanone 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanon 1-[2-(2-hydroxy-3-propylamino-propoxy)phenyl]-3-phenyl-propan-1-one 1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one 1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- (9CI) |
| CAS | 54063-53-5 |
| EINECS | 258-955-6 |
| InChI | InChI=1/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3 |
Propafenone USP - Physico-chemical Properties
| Molecular Formula | C21H27NO3 |
| Molar Mass | 341.44 |
| Density | 1.096±0.06 g/cm3(Predicted) |
| Boling Point | 519.6±50.0 °C(Predicted) |
| Flash Point | 268°C |
| Water Solubility | 759.9ug/L(22.5 ºC) |
| Vapor Presure | 1.27E-11mmHg at 25°C |
| pKa | pKa 9.27 (Uncertain) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.557 |
Propafenone USP - Risk and Safety
| Hazard Symbols | T - Toxic |
| Risk Codes | R46 - May cause heritable genetic damage R22 - Harmful if swallowed |
| Safety Description | S53 - Avoid exposure - obtain special instructions before use. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
| WGK Germany | 3 |
| RTECS | UH2833000 |
Propafenone USP - Reference Information
| NIST chemical information | Information provided by: webbook.nist.gov (external link) |
| highly effective class Ic antiarrhythmic drug | propafenone (propafenone), also known as xinluping, was first used clinically in Europe in 1977 and entered China in the early 1980 s. It is an efficient class Ic antiarrhythmic drug, which has the advantages of rapid onset, long action time, and definite curative effect. It is often used to treat ventricular or supraventricular premature beats, ventricular or supraventricular tachycardia, etc. Arrhythmia is one of the most widely used antiarrhythmic drugs in China. Pharmacological effects: Propafenone can reduce the depolarization of the systolic period, thus prolonging the conduction, the duration of the action potential and the effective refractory period are also slightly prolonged, and it can increase the threshold potential of myocardial cells and significantly reduce the spontaneous excitability of the myocardium. It not only acts on the atrium and ventricle (mainly affects Purkinje fibers, but has little effect on myocardium), but also acts on the formation and conduction of excitement. Clinical data show that the therapeutic dose (oral 300mg and intravenous 30mg) can reduce the stress of myocardium, the effect is lasting, the P-R interval and QRS wave are prolonged, the effective refractory period of atrium and atrioventricular node is prolonged, and it has an antagonistic effect on various types of experimental arrhythmia. The antiarrhythmic effect is related to its membrane stabilizing effect and competitive β-receptor blocking effect. It has a weak calcium channel blocking effect (100 times weaker than verapamil), and has a mild inhibitory effect on myocardium, increases end-stage diastolic blood pressure, and reduces stroke volume. Its effect is proportional to the dose of the drug. It also has a mild effect of lowering blood pressure and slowing heart rate. In vitro experiments show that propafenone can relax coronary artery and bronchial smooth muscle. It has a local anesthetic effect similar to that of procaine. Fig. 1 is the structural formula of propafenone |
| pharmacokinetics | oral absorption is good, the absorption rate is nearly 100%, but the first pass effect is obvious, and its bioavailability is dose-dependent, depending on the dose and dosage form. The antiarrhythmic effect reached a peak 2~3h after oral administration, and the effect could last for more than 8h. Plasma protein binding rate was 93%. This product is mainly excreted through the kidneys in the form of metabolites. The half-life (t1/2) is 3.5~4h. Clearance slows when severe liver damage occurs. It cannot be drained through dialysis. |
| Use | It is used for paroxysmal ventricular tachycardia, paroxysmal supraventricular tachycardia and preexcitation syndrome with supraventricular tachycardia, atrial flutter or atrial fibrillation. It can also be used for the treatment of various premature contractions (premature beats). |
| adverse reactions | 1. adverse reactions are less, including dry mouth, numbness of tongue and lips, and taste disturbance. 2. Headache, dizziness, nausea, vomiting, constipation, cholestatic liver damage, etc. 3. Sinoatrial node inhibition, atrioventricular block, prolonged Q-T interval, slightly prolonged P-R interval, prolonged QRS time, aggravating heart failure and bronchospasm, etc. |
| contraindications | patients with sinus node dysfunction without pacemaker protection, severe atrioventricular block, double bundle branch block, severe congestive heart failure, Cardiogenic shock, severe hypotension and allergy to the drug are contraindicated. (2016-01-30) |
| precautions | 1. use with caution in patients with severe myocardial damage. 2. Patients with severe bradycardia, liver and kidney insufficiency, and obvious hypotension should be used with caution. 3. If sinoatrial or atrioventricular conduction height block occurs, sodium lactate, atropine, isoprenaline or metahydroxyadrenaline can be injected intravenously to rescue. 4.FDA classified the pregnancy safety of this drug as Class C. |
| drug interaction | 1. combined with local anesthetics can increase the occurrence of side effects of central nervous system. 2. This product can increase the concentration of serum digoxin and is dose-dependent. 3. The combination of propranolol and metoprolol can significantly increase its plasma concentration and clearance half-life, but has no effect on propafenone. 4. When combined with warfarin can increase the blood concentration of warfarin and prothrombin time. 5. The combination with cimetidine can improve the steady-state level of propafenone, but has no effect on its electrophysiological parameters. 6. The combination of this product and other antiarrhythmic drugs, such as quinidine, verapamil, propranolol, etc. may increase the adverse reactions of this product. 7. Antihypertensive drugs can enhance the antihypertensive effect of this product. 8. Simultaneous application of local anesthetics may increase the adverse reactions of the central nervous system. 9. When combined with digoxin, this product increases the blood concentration of digoxin by 25% at 450mg per day and 85% at 900mg per day. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-10 22:29:15
Supplier List
Product Name: Propafenone Visit Supplier Webpage Request for quotation
CAS: 54063-53-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 54063-53-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Propafenone Visit Supplier Webpage Request for quotation
CAS: 54063-53-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 54063-53-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History